Thera-SAbDab

ONARTUZUMAB

>   Structural Summary
TherapeuticOnartuzumab
TargetMET
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK
100% seqID Fv Structure4k3j [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFab + di-Fc
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedChugai Pharmaceutical, Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer, Colorectal cancer, Gastric cancer, Glioblastoma, Liver cancer, Non-small cell lung cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]